Fisher et al., 1998 - Google Patents
Properties of poly (ethylene glycol)-conjugated red blood cellsFisher et al., 1998
- Document ID
- 14290221231997950139
- Author
- Fisher T
- Armstrong J
- Meiselman H
- Leger R
- Arndt P
- Garratty G
- Publication year
- Publication venue
- Blood Substitutes, Present and Future Perspectives
External Links
Snippet
Poly (ethylene glycol)(PEG) is an amphiphilic linear polymer, which is non-immunogenic, non-toxic and chemically inert in biological systems [1, 2]. Twenty years ago, Abuchowski et al.[3, 4] developed a technique to modify proteins by the covalent attachment of PEG, using …
- 229920001223 polyethylene glycol 0 title abstract description 133
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48169—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being an organic macromolecular compound, i.e. an oligomeric, polymeric, dendrimeric molecule
- A61K47/48192—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being an organic macromolecular compound, i.e. an oligomeric, polymeric, dendrimeric molecule the organic macromolecular compound has been obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas, polyurethanes
- A61K47/48215—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being an organic macromolecular compound, i.e. an oligomeric, polymeric, dendrimeric molecule the organic macromolecular compound has been obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas, polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer, dendrimer, e.g. PEG, PPG, PEO, polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6129912A (en) | Polyethylene glycol-protein compositions which reduce the antigenic display of red blood cells | |
US10441606B2 (en) | Polymers for reversing heparin-based anticoagulation | |
Bradley et al. | Biophysical consequences of linker chemistry and polymer size on stealth erythrocytes: size does matter | |
AU637996B2 (en) | Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids | |
JP2647556B2 (en) | Polyoxypropylene / polyoxyethylene copolymers with improved biological activity | |
Vert et al. | Poly (ethylene glycol): protein-repulsive or albumin-compatible? | |
US20070212300A1 (en) | Delivery of compounds with rehydrated blood cells | |
US6312685B1 (en) | Red blood cells covalently bound with two different polyethylene glycol derivatives | |
Armstrong et al. | Modulation of red blood cell aggregation and blood viscosity by the covalent attachment of Pluronic copolymers | |
EP0901521A1 (en) | Antigenic modulation of cells | |
Wang et al. | Polymer-mediated immunocamouflage of red blood cells: effects of polymer size on antigenic and immunogenic recognition of allogeneic donor blood cells | |
US20030207247A1 (en) | Preparation of red blood cells having reduced immunogenicity | |
Fisher et al. | Properties of poly (ethylene glycol)-conjugated red blood cells | |
US11123441B2 (en) | Methods and compositions for drug delivery | |
Emanuele | FLOCOR™: a new anti-adhesive, rheologic agent | |
US6942859B2 (en) | Red blood cells covalently bound with polymers | |
WO2004050848A2 (en) | Methods for antigen masking of red blood cells resulting in reduced hemolysis | |
US8007784B1 (en) | Antigenic modulation of cells | |
Scott et al. | The other blood substitute: antigenically inert erythrocytes | |
Gill | Resealed erythrocytes as a potential drug carrier system | |
Garratty | Will stealth RBCs replace blood donors of rare types? | |
HASHEMI et al. | Factorial design optimization of red blood cell PEGylation with a low molecular weight polymer | |
Sarvi et al. | Surface treatment of red blood cells with monomethoxypoly (ethylene glycol) activated by succinimidyl carbonate | |
Sarvi et al. | Surface coating of red blood cells with monomethoxy poly (ethylene glycol) activated with two different reagents | |
Cerda Cristerna | Hemocompatibility and camouflaging efficiency of functionalized poly (dimethylamino-ethylmethacrylate) based polymers |